Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab with HyperCVAD/MA for Newly Diagnosed Mantle Cell Lymphoma
NCT01527149Phase 2Completed
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Dec 2011
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in mantle cell lymphoma (MCL), sponsored by Roswell Park Comprehensive Cancer Center. Primary endpoints: Overall Response Rate at 22 weeks and Complete Remission Rate at 22 weeks. Started Dec 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT01527149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527149.